Wellington Management Group
VKTX icon

Wellington Management Group’s Viking Therapeutics VKTX Stock Holding History

Wellington Management Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39,835
Closed -$2.11M – 2034
2024
Q2 		$2.11M Buy
39,835
+4,664
+13% +$306K ﹤0.01% 1502
2024
Q1 		$2.88M Buy
+35,171
New +$1.56M ﹤0.01% 1448
2023
Q2 		– Sell
-164,288
Closed -$2.74M – 2015
2023
Q1 		$2.74M Buy
+164,288
New +$1.7M ﹤0.01% 1431
2020
Q1 		– Sell
-62,088
Closed -$498K – 2057
2019
Q4 		$498K Sell
62,088
-38,888
-39% -$283K ﹤0.01% 1856
2019
Q3 		$694K Sell
100,976
-32,992
-25% -$245K ﹤0.01% 1802
2019
Q2 		$1.11M Buy
133,968
+32,001
+31% +$273K ﹤0.01% 1742
2019
Q1 		$1.01M Buy
101,967
+62,236
+157% +$521K ﹤0.01% 1762
2018
Q4 		$304K Buy
+39,731
New +$475K ﹤0.01% 1972

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Wellington Management Group's VKTX Position: Q3 2024 in Review

Wellington Management Group sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 39,835 shares — an estimated $2.11M sold.

Wellington Management Group first reported a position in VKTX in Q4 2018 and held it in 8 quarters. The position peaked at $2.88M in Q1 2024. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Wellington Management Group reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Wellington Management Group sold 39,835 Viking Therapeutics shares in Q3 2024, an estimated $2.11M.
  • Wellington Management Group first reported a position in Viking Therapeutics in Q4 2018 and held it in 8 quarters.
  • Wellington Management Group's Viking Therapeutics position peaked at $2.88M in Q1 2024.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Wellington Management Group's 13F filing for Q3 2024, filed 14 Nov 2024.